摘要特发性肺纤维化（ IPF）是一种原因未明的纤维化型的间质性肺炎，患者中位生存期只有2～3年，因此，及时的诊断和治疗尤为重要。目前Ⅱ型肺泡细胞表面抗原（ KL-6）、肺表面活性蛋白A（ SP-A）和肺表面活性蛋白D（ SP-D）在国外被应用于临床，有较好的敏感度，并能预示疾病的进展和预后，但是在诊断的特异性上存在不足。尚有一些处于研究早期的潜在生物学标志物，以期研究能发现高度特异性和敏感度的生物学标志物。本文主要从与IPF的病理生理机制有关的肺泡内皮细胞功能紊乱、肺纤维化和免疫系统功能紊乱3个方面阐释近年来生物学标志物的研究。（中华检验医学杂志，2016，39：68-70）

abstractsIdiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown etiology , a median survival time of which is 2 to 3 years.The diagnosis and treatment are important for IPF in time.Krebs von den lungen-6(KL-6), Surfactant protein-A(SP-A) and Surfactant protein-D(SP-D) are acceptable biomarkers in clinical for idiopathic pulmonary fibrosis in Japan,which have shown good sensitivity at diagnosis IPF and predict the prognoses for patients with IPF . However , the differential diagnosis of IPF from other interstitial lung diseases is still challenging .Other biomarkers are being developed , one of which would have the best specificity and sensitivity at diagnosis IPF.Those biomarkers about pathogenesis of IPF includes alveolar epithelial cell dysfunction , fibrogenesis and immune dysregulation are shown .They are potential to account for underlying disease mechanisms , accelerated drug development and advance clinical management.